PDCD1 and gastric cancer: Lentinan serves synergistic actions with a molecular targeting agent and cytotoxic drugs through the modulation of ADCC or PD-1/PD-L1 axis, which may support the idea that the chemo-immunotherapy prolongs the survival of metastatic gastric cancer patients, compared to chemotherapy alone.